Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir Fathi(Massachusetts General Hospital), Yi‐Bin Chen(Massachusetts General Hospital), Ashkan Emadi(University of Maryland, Baltimore), Katherine M. Edmonds(Harvard University), Meghan Burke(Harvard University), David P. Schenkein(Agios Pharmaceuticals (United States)), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Kimberly Straley(Agios Pharmaceuticals (United States)), Katharine Yen(Agios Pharmaceuticals (United States)), A. John Iafrate(Massachusetts General Hospital), Hector U. Lopez(Harvard University), Richard M. Stone(Dana-Farber Cancer Institute), Christina R. Matulis(Harvard University), Cedric T. Hill(Harvard University), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Samuel Agresta(Agios Pharmaceuticals (United States)), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Donna Neuberg(Otsuka (Japan)), Julia Foster(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 123
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k